Shanghai Longwood Biopharmaceuticals Co., Ltd.
Clinical trials sponsored by Shanghai Longwood Biopharmaceuticals Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hepatitis b drug enters human trials – could it help control the virus? Results expected Mar 2027 (estimated)
-
New hepatitis b drug enters human trials – could it help control the virus?
Disease control Recruiting nowThis study tests a new medicine, LW231, in people with chronic hepatitis B. The goal is to see if it is safe and can lower the amount of virus in the blood. Some participants will get LW231 alone, others will get it together with standard antiviral pills. The trial involves about…
Phase 1/2 • Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New pill could ease severe eczema in major trial
Symptom relief Recruiting nowThis phase 3 study tests an oral tablet called LW402 in 480 adults with moderate-to-severe atopic dermatitis (eczema). Participants will take either the drug or a placebo daily for 16 weeks. The goal is to see if LW402 can significantly improve eczema severity and skin clearance …
Phase 3 • Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. • Aim: Symptom relief
Last updated Aug 29, 2026 00:00 UTC